Enlaza Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-09-11.
Enlaza Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 11, 2025. The filing reports $15M sold. Its industry group is Pharmaceuticals. It names Sergio Duron (Executive Officer, Director), Sanford Madigan (Executive Officer), Tighe Reardon (Executive Officer) (SEC Form D, September 11, 2025).
Is this your company?
Sell to companies like Enlaza Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-09-11 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Enlaza Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Enlaza Therapeutics, Inc., from the filings we hold.
Pharmaceuticals raises by companies based in California, filed within 90 days of this one, largest first.
Get an email when Enlaza Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Enlaza Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Enlaza Therapeutics, Inc. →Get the full cited report on Enlaza Therapeutics, Inc.
What the filing shows about Enlaza Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Enlaza Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Enlaza Therapeutics, Inc.'s address as 11099 North Torrey Pines Road, Ste. 280, La Jolla, CA 92037.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Enlaza Therapeutics, Inc. See pricing
Enlaza Therapeutics, Inc. is a registered filer with the SEC (CIK 1852950) and has filed since 2022-10-13. 5 filings are on record, the latest on 2025-09-11.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Enlaza Therapeutics, Inc.'s Form D of 2025-09-11 names Sergio Duron, Sanford Madigan, Tighe Reardon and 5 more as its officers, directors or promoters.
Its new offerings report $99M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Sergio Duron is named as Executive Officer and Director on the Form D that Enlaza Therapeutics, Inc. filed with the SEC on 11 September 2025, one of 8 people that filing names.
Sanford Madigan is named as Executive Officer on the Form D that Enlaza Therapeutics, Inc. filed with the SEC on 11 September 2025, one of 8 people that filing names.
Tighe Reardon is named as Executive Officer on the Form D that Enlaza Therapeutics, Inc. filed with the SEC on 11 September 2025, one of 8 people that filing names.
Jay Lichter is named as Director on the Form D that Enlaza Therapeutics, Inc. filed with the SEC on 11 September 2025, one of 8 people that filing names.
Shelley Chu is named as Director on the Form D that Enlaza Therapeutics, Inc. filed with the SEC on 11 September 2025, one of 8 people that filing names.
James Topper is named as Director on the Form D that Enlaza Therapeutics, Inc. filed with the SEC on 11 September 2025, one of 8 people that filing names.
Marcos Milla is named as Director on the Form D that Enlaza Therapeutics, Inc. filed with the SEC on 11 September 2025, one of 8 people that filing names.
Stephen Squinto is named as Director on the Form D that Enlaza Therapeutics, Inc. filed with the SEC on 11 September 2025, one of 8 people that filing names.
8 people named on the filing — 3 holding an executive role and 5 as directors only.
Named as of the 2025-09-11 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Enlaza Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Enlaza Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Enlaza Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Enlaza Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Enlaza Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Enlaza Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/enlaza-therapeutics-inc-form-d-25000001